Oxcarbazepine metabolite (MHD) assay
Oxcarbazepine is a pro-drug indicated for treatment of partial seizures, a form of epilepsy. Serum concentrations (3-35 mg/L) of the active monohydroxy derivative (MHD) metabolite are associated with clinically effective control of partial seizures. Toxic side effects may occur more commonly at concentrations greater than 35 mg/L. Therapeutic drug monitoring (TDM) is justified when changes are expected that might alter MHD clearance including pregnancy, concomitant use of liver enzyme inducing drugs, or renal insufficiency. The ARK Oxcarbazepine Metabolite Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of MHD in human serum on automated clinical chemistry analysers. The ARK Oxcarbazepine Metabolite Assay is available for export outside the US. It has not received clearance/approval by the U.S. FDA.
Supplier: ARK Diagnostics, Inc
Website:
